AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2810673 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin and Gemfibrozil
Number of subjects: 22
Study 31089256 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 189
Study 27569255 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D + B vitamins
Number of subjects: 52
Study 27569255 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D
Number of subjects: 52
Study 25973809 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Touches intervention
Number of subjects: 492
Study 25973809 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 492
Study 24716248 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Restorative Treatment (CRT)
Number of subjects: 302
Study 24716248 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART)
Number of subjects: 302
Study 24716248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Conservative Treatment (UCT)
Number of subjects: 302
Study 24716248 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 302
Study 21301356 — intervention group
Group type: EXPERIMENTAL
Intervention: C-D score method
Number of subjects: 84
Study 21301356 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation severity by VAS
Number of subjects: 84
Study 19299409 — intervention group
Group type: EXPERIMENTAL
Intervention: Personally tailored feedback based on lung functioning, CO exposure, and smoking-related health conditions
Number of subjects: 536
Study 19299409 — intervention group
Group type: COMPARATOR
Intervention: Generic information about the risks of smoking and personalized counseling based on diet, body mass index, and physical activity
Number of subjects: 536
Study 19299409 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with impaired lung functioning
Number of subjects: 536
Study 19299409 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group without impaired lung functioning
Number of subjects: 536
Study 18174971 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 18174971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15895759 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin plus aspirin (WA) (n = 418)
Number of subjects: 831
Study 15895759 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (n = 413)
Number of subjects: 831
Study 12238845 — intervention group
Group type: EXPERIMENTAL
Intervention: Capiox poly(2‐methoxyethylacrylate) coated SX18R oxygenators with noncoated circuits
Number of subjects: 60
Study 12238845 — intervention group
Group type: COMPARATOR
Intervention: Noncoated oxygenator fibers
Number of subjects: 60
Study 9718228 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate 40/50 mg
Number of subjects: 605
Study 9718228 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate 60/80 mg
Number of subjects: 605
Study 9718228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study 7863722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable pyrantel pamoate tablets (swallow whole)
Number of subjects: 0
Study 7863722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable pyrantel pamoate tablets (chew and swallow)
Number of subjects: 0
Study 7863722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable pyrantel pamoate tablets (pulverized)
Number of subjects: 0
Study 2644954 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 266
Study 2644954 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and Radiation Therapy
Number of subjects: 266
Study 2644954 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 266
Study 235144 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance amitriptyline for eight months
Number of subjects: 0
Study 235144 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly psychotherapy
Number of subjects: 0
Study 235144 — intervention group
Group type: EXPERIMENTAL
Intervention: Once monthly psychotherapy
Number of subjects: 0
Study 235144 — intervention group
Group type: COMPARATOR
Intervention: Double-blind withdrawal
Number of subjects: 0
Study 235144 — intervention group
Group type: COMPARATOR
Intervention: Overt withdrawal
Number of subjects: 0
Study 31197436 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg prazosin
Number of subjects: 64
Study 31197436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 28257875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined WM, IC, and neurofeedback training using Focus Pocus software, 25 sessions over 7 to 8 weeks
Number of subjects: 85
Study 28257875 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 85
Study 26409698 — intervention group
Group type: EXPERIMENTAL
Intervention: mCIMT + TR
Number of subjects: 18
Study 26409698 — intervention group
Group type: COMPARATOR
Intervention: mCIMT
Number of subjects: 18
Study 24129363 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g-organic naked oat with whole germ group (ONOG)
Number of subjects: 260
Study 24129363 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g-organic naked oat with whole germ group (ONOG)
Number of subjects: 260
Study 24129363 — intervention group
Group type: COMPARATOR
Intervention: diet group (systematic diet plans and intensive education)
Number of subjects: 260
Study 24129363 — intervention group
Group type: COMPARATOR
Intervention: usual care group (control group, only basic health advice)
Number of subjects: 260
Study 21693504 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in systolic blood pressure (SBP) during treatment
Number of subjects: 386
Study 21693504 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure reduction (relative change > median)
Number of subjects: 386
Study 21693504 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure reduction
Number of subjects: 386
Study 21693504 — intervention group
Group type: EXPERIMENTAL
Intervention: No systolic blood pressure reduction
Number of subjects: 386
Study 18274852 — intervention group
Group type: EXPERIMENTAL
Intervention: Finalized questionnaire administered to patients
Number of subjects: 369
Study 18274852 — intervention group
Group type: EXPERIMENTAL
Intervention: Finalized questionnaire
Number of subjects: 369
Study 17123908 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet pellet/guided tissue regeneration (PP/GTR)
Number of subjects: 15
Study 17123908 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass/guided tissue regeneration (BG/GTR)
Number of subjects: 15
Study 15580194 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (1mg/m2/day)
Number of subjects: 29
Study 11531901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sferics measurement (low frequency, low intensity electromagnetic pulses)
Number of subjects: 21
Study 9201877 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler assessment of uterine and uteroplacental circulation
Number of subjects: 175
Study 8273900 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 132
Study 8273900 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IVPCA) with 10 mg pethidine
Number of subjects: 132
Study 8273900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia (IVPCA) with 20 mg pethidine
Number of subjects: 132
Study 2952868 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic drainage of abdominal wounds with a closed suction system
Number of subjects: 0
Study 2952868 — intervention group
Group type: COMPARATOR
Intervention: No drainage (control group)
Number of subjects: 0
Study 29294081 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Possible Self intervention
Number of subjects: 71
Study 29294081 — intervention group
Group type: COMPARATOR
Intervention: Daily Activities control condition
Number of subjects: 71
Study 27342586 — intervention group
Group type: EXPERIMENTAL
Intervention: Young subjects with visual impairment (age ≤40 years)
Number of subjects: 324
Study 27342586 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly subjects with visual impairment (age >40 years)
Number of subjects: 324
Study 27342586 — intervention group
Group type: COMPARATOR
Intervention: Subjects without visual impairment (both age groups)
Number of subjects: 324
Study 25437697 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 25437697 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulphate
Number of subjects: 60
Study 25437697 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 23426037 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea catechins (GTCs) with or without caffeine
Number of subjects: 1584
Study 23426037 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 1584
Study 20844475 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 20844475 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 18261537 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E) 10 mg/d
Number of subjects: 76
Study 18261537 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (L) 50 mg/d
Number of subjects: 76
Study 18261537 — intervention group
Group type: COMPARATOR
Intervention: Enalapril + Losartan (E(+)L(+): 10 mg/d + 50 mg/d)
Number of subjects: 76
Study 18261537 — intervention group
Group type: COMPARATOR
Intervention: No medication (E(−):L(−))
Number of subjects: 76
Study 15842584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 82
Study 15842584 — intervention group
Group type: COMPARATOR
Intervention: Patients with YMDD mutations
Number of subjects: 82
Study 14608128 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin high-dose group (1 mg/kg bolus; 2.5 mg/kg/hour infusion for 4 hours)
Number of subjects: 52
Study 14608128 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin low-dose group (0.75 mg/kg bolus; 1.75 mg/kg/hour infusion)
Number of subjects: 52
Study 14608128 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (both high and low dose)
Number of subjects: 52
Study 10838464 — intervention group
Group type: EXPERIMENTAL
Intervention: CF supplementation (1 mg beta-carotene/kg body weight/day for 12 weeks, then 10 mg beta-carotene/day for the next 12 weeks)
Number of subjects: 24
Study 10838464 — intervention group
Group type: COMPARATOR
Intervention: CF placebo
Number of subjects: 24
Study 9088815 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection technique (45 mL of mepivacaine 1% with adrenaline 5 micrograms mL‐1)
Number of subjects: 80
Study 9088815 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple injections technique (45 mL of mepivacaine 1% with adrenaline 5 micrograms mL‐1)
Number of subjects: 80
Study 9088815 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection technique (after supplementation)
Number of subjects: 80
Study 9088815 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple injections technique (after supplementation)
Number of subjects: 80
Study 9088815 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 80
Study 8462363 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose octreotide (N = 9)
Number of subjects: 19
Study 3770281 — intervention group
Group type: EXPERIMENTAL
Intervention: Buphenine hydrochloride
Number of subjects: 170
Study 3770281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 29644874 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-prohibited (intervention)
Number of subjects: 112
Study 29644874 — intervention group
Group type: COMPARATOR
Intervention: Device-allowed (control)
Number of subjects: 112
Study 26911132 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP reduction in patients receiving AVR
Number of subjects: 1423
Study 26911132 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP reduction in patients not receiving AVR
Number of subjects: 1423
Study 26911132 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP1 as a predictor for AVR
Number of subjects: 1423
Study 26911132 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP0 as a predictor for AVR
Number of subjects: 1423
Study 26911132 — intervention group
Group type: EXPERIMENTAL
Intervention: AVR rates based on hsCRP changes
Number of subjects: 1423
Study 26911132 — intervention group
Group type: EXPERIMENTAL
Intervention: AVR rates in patients with reduced hsCRP
Number of subjects: 1423
Study 24611923 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-Assisted Problem Solving (CAPS)
Number of subjects: 132
Study 24611923 — intervention group
Group type: COMPARATOR
Intervention: Information-based Internet Resource Comparison (IRC)
Number of subjects: 132
Study 21678169 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (II)
Number of subjects: 163
Study 21678169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of implementation intentions and self-efficacy (II + SE)
Number of subjects: 163
Study 21678169 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy (SE)
Number of subjects: 163
Study 21678169 — intervention group
Group type: COMPARATOR
Intervention: Control group (written information on nutrition)
Number of subjects: 163
Study 20147968 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml of fermented milk (FM)
Number of subjects: 94
Study 20147968 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ml of fermented milk (FM)
Number of subjects: 94
Study 20147968 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chemically acidified milk)
Number of subjects: 94
Study 18400556 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS)
Number of subjects: 9
Study 18400556 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 9
Study 18400556 — intervention group
Group type: COMPARATOR
Intervention: Conventional rTMS paradigms
Number of subjects: 9
Study 18400556 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric monophasic pulse with posteriorly directed current flow
Number of subjects: 9
Study 18400556 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-sine pulse with postero-anterior current
Number of subjects: 9
Study 18400556 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic stimuli
Number of subjects: 9
Study 15842266 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% PHMB mouthrinse (A)
Number of subjects: 16
Study 15842266 — intervention group
Group type: COMPARATOR
Intervention: 0.12% aqueous chlorhexidine solution (B)
Number of subjects: 16
Study 15842266 — intervention group
Group type: COMPARATOR
Intervention: 0.3% triclosan/2.0% copolymer mouthrinse (C)
Number of subjects: 16
Study 15842266 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse (10% ethanol, flavour) (D)
Number of subjects: 16
Study 12458403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 46
Study 12458403 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to Cold Pressor Test (CPT)
Number of subjects: 46
Study 12458403 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT- group
Number of subjects: 46
Study 12458403 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 46
Study 9666765 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic prophylaxis with 1 g of ceftriaxone intravenously 1-2 hours before surgery
Number of subjects: 127
Study 9666765 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 127
Study 7634503 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose r‐hGH (40 IU/m2/week)
Number of subjects: 29
Study 7634503 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose r‐hGH (20 IU/m2/week)
Number of subjects: 29
Study 7634503 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 29
Study 7634503 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hGH therapy
Number of subjects: 29
Study 3398652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin and metronidazole (group A)
Number of subjects: 330
Study 3398652 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin alone (group B)
Number of subjects: 330
Study 31362034 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-anodal tDCS (2 mA, twice-daily sessions for five consecutive days)
Number of subjects: 60
Study 31362034 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-anodal tDCS
Number of subjects: 60
Study 31362034 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 60
Study 29608039 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% HOCl
Number of subjects: 75
Study 29608039 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% HOCl
Number of subjects: 75
Study 29608039 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% CHX
Number of subjects: 75
Study 29608039 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CHX
Number of subjects: 75
Study 29608039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 29608039 — intervention group
Group type: EXPERIMENTAL
Intervention: HOCl
Number of subjects: 75
Study 26156961 — intervention group
Group type: EXPERIMENTAL
Intervention: WM training with a rehearsal strategy
Number of subjects: 58
Study 26156961 — intervention group
Group type: EXPERIMENTAL
Intervention: WM training without strategy instruction
Number of subjects: 58
Study 26156961 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 58
Study 25791116 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated recombinant tetravalent dengue vaccine candidate (TDV), given in 2 doses 90 days apart
Number of subjects: 72
Study 23583618 — intervention group
Group type: EXPERIMENTAL
Intervention: VR simulator warm-up (3-5 minutes)
Number of subjects: 51
Study 23583618 — intervention group
Group type: COMPARATOR
Intervention: Leisure book reading (10 minutes)
Number of subjects: 51
Study 20971463 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ICSI technique using zona pellucida (ZP)-bound sperm; n = 53 couples
Number of subjects: 106
Study 20971463 — intervention group
Group type: COMPARATOR
Intervention: Conventional intracytoplasmic sperm injection (ICSI); n = 53 couples
Number of subjects: 106
Study 19930363 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Supervision implementation
Number of subjects: 0
Study 16723319 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmedicated schizophrenia patients
Number of subjects: 100
Study 16723319 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated schizophrenia patients
Number of subjects: 100
Study 16723319 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 100
Study 16723319 — intervention group
Group type: EXPERIMENTAL
Intervention: Acutely psychotic schizophrenia patients (medicated and unmedicated)
Number of subjects: 100
Study 16723319 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial remission schizophrenia patients (medicated)
Number of subjects: 100
Study 15640943 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha
Number of subjects: 134
Study 11355749 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.025 mg/kg BW/day)
Number of subjects: 27
Study 11355749 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I (0.015 mg/kg BW/day)
Number of subjects: 27
Study 11355749 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH + rhIGF-I
Number of subjects: 27
Study 11355749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 27
Study 9383694 — intervention group
Group type: COMPARATOR
Intervention: Cervical hip fracture group (n=42)
Number of subjects: 233
Study 9383694 — intervention group
Group type: COMPARATOR
Intervention: Trochanteric hip fracture group (n=24)
Number of subjects: 233
Study 9383694 — intervention group
Group type: COMPARATOR
Intervention: Cervical hip fracture prediction
Number of subjects: 233
Study 7955256 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 748
Study 7955256 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 748
Study 7955256 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation or antiplatelet therapy
Number of subjects: 748
Study 7955256 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 748
Study 4012240 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin 8 g plus cloxacillin 4 g daily for three days
Number of subjects: 100
Study 4012240 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin 8 g daily for three days
Number of subjects: 100
Study 28913630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Position Trainer (SPT)
Number of subjects: 99
Study 28913630 — intervention group
Group type: COMPARATOR
Intervention: Oral Appliance Therapy (OAT)
Number of subjects: 99
Study 26810242 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexanide (PLX)
Number of subjects: 100
Study 26810242 — intervention group
Group type: COMPARATOR
Intervention: Saline + Povidone Iodine (PY)
Number of subjects: 100
Study 25131484 — intervention group
Group type: EXPERIMENTAL
Intervention: IUPU technique group (n = 193)
Number of subjects: 378
Study 25131484 — intervention group
Group type: COMPARATOR
Intervention: Routine manipulation group (n = 185)
Number of subjects: 378
Study 22157392 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin ophthalmic solution 1% administered bid on days 1 and 2 and on days 3 to 29±1
Number of subjects: 50
Study 22157392 — intervention group
Group type: COMPARATOR
Intervention: Visine for Contacts rewetting drops administered qid on days 1 to 29±1
Number of subjects: 50
Study 22157392 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin ophthalmic solution 1%
Number of subjects: 50
Study 20502065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 0
Study 20502065 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 0
Study 18239749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose oral corticosteroids
Number of subjects: 0